S-1/A: FibroBiologics Enters Engagement with Maxim Group LLC for Financial Advisory Services

FibroBiologics, Inc. has engaged Maxim Group LLC as its financial advisor and investment banker to provide general financial advisory and investment banking services, including assistance with a potential direct listing or other go-public transactions.

Summary

• FibroBiologics, Inc. has retained Maxim Group LLC as its financial advisor and investment banker.
• Maxim will provide general financial advisory and investment banking services, including strategic planning, analysis of markets, financial models, and potential strategic alliances.
• Maxim will advise on matters relating to a direct listing to a major U.S. exchange, initial public offering, SPAC business combination, reverse merger into a public company or other transaction that results in the Company's listing on a major U.S. exchange.
• Maxim will assist in the preparation of a registration statement and coordinate with the Financial Regulatory Authority in the event of a direct listing.
• Maxim will coordinate with the Company's chosen U.S. national securities exchange in relation to informing such exchange as to the readiness of the Company's shares to trade and other matters related to a direct listing.
• Maxim will advise and assist the Company in informing its shareholders through investor education and investor day events in the case of a direct listing.
• Maxim will advise the Company on potential financing alternatives, including facilitation and negotiation of any financial or structural aspects of such alternatives.
• The Company will cooperate with Maxim and furnish all necessary information regarding the business, operations, properties, financial condition, management, and prospects of the Company.
• The Company will reimburse Maxim for all reasonable, documented expenses, including legal fees and travel expenses, up to $5,000 without prior authorization, with an exception for legal fees less than $10,000.
• The Company agrees to indemnify Maxim against losses arising from Maxim's services, except those resulting from Maxim's gross negligence or willful misconduct.
• For a period of nine months after a Go-Public Transaction, the Company shall offer to retain Maxim as its lead underwriter, placement agent, or advisor for any public offering, private placement, or other financing or transaction.
• Either party may terminate the agreement with 30 days' written notice after the five-month anniversary of the agreement, unless terminated for cause.
• Any controversy between the parties will be resolved by arbitration before the American Arbitration Association (AAA) in New York City.

Sentiment

Score: 7

Explanation: The document is a standard engagement letter, indicating a positive step for FibroBiologics in seeking financial advisory services. The terms are generally favorable and reflect industry norms.

Positives

• The engagement of Maxim Group LLC provides FibroBiologics with expert financial advisory services.
• Maxim's expertise can assist FibroBiologics in navigating complex transactions such as a direct listing or IPO.
• The agreement includes indemnification provisions that protect Maxim from liabilities, except in cases of gross negligence or willful misconduct.
• The agreement provides FibroBiologics with access to Maxim's network and expertise in potential financing alternatives.

Negatives

• The agreement includes fees payable to Maxim upon the closing of any Go-Public Transactions during that period by the Company.
• The Company is obligated to offer Maxim the opportunity to act as lead underwriter, placement agent, or advisor for future financings or transactions for a period of nine months after a Go-Public Transaction.
• The Company is responsible for reimbursing Maxim's expenses, which could add to the overall cost of the engagement.

Risks

• The success of the engagement depends on the accuracy and completeness of the information provided by FibroBiologics to Maxim.
• The agreement can be terminated by either party with 30 days' notice, which could disrupt FibroBiologics' strategic plans.
• Disputes between FibroBiologics and Maxim will be resolved through arbitration, which may be costly and time-consuming.
• The indemnification provisions may not cover all potential liabilities, leaving FibroBiologics exposed to certain risks.

Future Outlook

The agreement outlines the terms for potential future engagements, including the Company offering Maxim the opportunity to act as lead underwriter, placement agent, or advisor for future financings or transactions for a period of nine months after a Go-Public Transaction.

Management Comments

• Mr. Peter OHeeron, Chairman & CEO of FibroBiologics, Inc., agreed to and accepted the terms of the engagement with Maxim Group LLC.

Industry Context

The engagement of a financial advisor is a common practice for companies considering a public listing or other significant financial transactions. Maxim Group LLC is an established investment bank with experience in advising companies in various industries.

Comparison to Industry Standards

• The fees outlined in the agreement, such as 7% for capital raised in an IPO and 2% for M&A transactions, are within the typical range for investment banking services.
• The warrant coverage of 4% is also within the standard range for similar transactions.
• Indemnification provisions are standard in engagement letters to protect the financial advisor from liabilities arising from their services.

Stakeholder Impact

• Shareholders may benefit from the potential increase in company value through strategic planning and access to capital markets.
• Employees may see increased job security and opportunities for growth as the company pursues strategic initiatives.
• Customers may benefit from improved products and services as the company strengthens its financial position.

Next Steps

• Maxim Group LLC will begin providing financial advisory and investment banking services to FibroBiologics, Inc.
• FibroBiologics will cooperate with Maxim and provide necessary information for the advisory services.
• The parties will work towards potential Go-Public Transactions or other financing alternatives.

Key Dates

Keywords

financial advisor, investment banker, Maxim Group LLC, FibroBiologics, direct listing, IPO, SPAC, merger, acquisition, financing, advisory services